Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infiltration Clear all
Withdrawn Phase 4 Interventional

Adductor Canal Vs Adductor Canal Plus SPANK Block for Postoperative Pain in Knee Arthroplasty Surgery

NCT04290442
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Anesthesia, Conduction, Acute Pain
Interventions
adductor canal block, SPANK, Ropivacaine
Procedure · Drug
Lead sponsor
Bruce Ben-David
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 23, 2026, 10:26 AM EDT
Not yet recruiting Phase 2 Interventional

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

NCT07720180
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 10:26 AM EDT
Withdrawn Not applicable Interventional

Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

NCT04429204
View directory record Official record
Conditions
Mesothelioma
Interventions
Biospecimen Collection, Cryosurgery
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 10:26 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
View directory record Official record
Conditions
Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty

NCT03234374
View directory record Official record
Conditions
Hernioplasty
Interventions
INL-001 (bupivacaine HCl collagen implant), Marcaine 0.25% infiltration
Combination Product · Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Anniston, Alabama • Longwood, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 23, 2026, 10:26 AM EDT
Suspended Not applicable Interventional

ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma

NCT03322813
View directory record Official record
Conditions
Glioma
Interventions
ExAblate 4000 - Type 2
Device
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration

NCT02658240
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ropivacaine, Epinephrine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

NCT04111510
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Tumor infiltrating lymphocytes (TIL) LN-145
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty

NCT03653416
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Ipack, Bupivacaine, Peri Articular Infiltration
Device · Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 2 Interventional

Erector Spinae Plane Block vs Local Infiltration Following Fusion Surgery

NCT06199999
View directory record Official record
Conditions
Postoperative Delirium, Pain, Postoperative, Degenerative Disc Disease
Interventions
Erector Spinae Block, Local infiltration with local anesthetic
Procedure
Lead sponsor
Rashmi Mueller
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 10:26 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

NCT04300231
View directory record Official record
Conditions
Cystectomy
Interventions
epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional

Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery

NCT05494645
View directory record Official record
Conditions
Pain, Postoperative, Pain, Acute Postoperative, Ankle Fractures, Ankle Injuries and Disorders
Interventions
Exparel, Peripheral Nerve Block
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 23, 2026, 10:26 AM EDT
Terminated Not applicable Interventional

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

NCT03889093
View directory record Official record
Conditions
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Interventions
Yttrium-90
Other
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 23, 2026, 10:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Post-operative Pain After Direct Anterior Total Hip Arthroplasty

NCT02904993
View directory record Official record
Conditions
Degenerative Joint Disease
Interventions
L2 paravertebral block, periarticular injection group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars

NCT01496846
View directory record Official record
Conditions
Irreversible Pulpitis
Interventions
IANB Articaine, SUP Articaine, SUP Lidocaine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Results available

TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy

NCT02519023
View directory record Official record
Conditions
Acute Pain
Interventions
Liposomal Bupivacaine, Bupivacaine, Ultrasound, Epinephrine, acetaminophen, ibuprofen, Oxycodone
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 23, 2026, 10:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Interventions
IOV-3001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 10:26 AM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 23, 2026, 10:26 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

NCT03545516
View directory record Official record
Conditions
Pain, Postoperative, Anesthesia, Local, Opioid Use
Interventions
Bupivacaine, Dexmedetomidine, Placebo
Drug
Lead sponsor
Richmond University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 23, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Optical Detection of Intravenous Infiltration:A Pilot Study

NCT02553421
View directory record Official record
Conditions
Infiltration of Peripheral IV Therapy
Interventions
ivWatch Model 400
Device
Lead sponsor
ivWatch, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 23, 2026, 10:26 AM EDT